Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network

Janet Carpenter, Katherine M. Newton, Barbara Sternfeld, Hadine Joffe, Susan D. Reed, Kristine E. Ensrud, Jennifer L. Milata

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: The aim of this study was to evaluate monitors for assessing vasomotor symptoms (VMS) in laboratory and ambulatory settings before use in the Menopause Strategies Finding Lasting Answers for Symptoms and Health network clinical trials testing VMS therapies. Methods: This was a three-phase study. Phase 1 included laboratory testing of the Freedman and prototype Bahr Monitor, phase 2 included laboratory testing of the commercial Bahr Monitor and Biolog, and phase 3 included ambulatory testing of the commercial Bahr Monitor and Biolog. All phases enrolled midlife women with VMS, midlife women without VMS, and young women without VMS. The participants self-reported VMS by pressing event marker buttons. Questionnaires assessed demographics (all phases) and monitor acceptability (phases 2 and 3). Results: Phase I testing was stopped because of sensitivity of the Freedman device to ambient humidity changes and lack of analytic software for the prototype Bahr Monitor. In phases 2 and 3, agreement between event-marked and commercial Bahr Monitor or Biolog-recorded VMS was higher in the laboratory than in the ambulatory setting; however, agreement between monitors was poor in two of three laboratory groups (midlife no VMS and young no VMS) and in all ambulatory groups. During ambulatory monitoring, the mean number of Bahr Monitor VMS was 16.33 in midlife women with VMS, 9.61 in midlife women without VMS, and 14.63 in young women without VMS (software version, March 2011). The Bahr Monitor was more acceptable than the larger Biolog, but feedback reflected annoyance at having to wear a device that itched and was visible under clothing. Conclusions: The Bahr Monitor and Biolog seem suitable for use in controlled laboratory conditions during short periods of time. However, the current versions of these monitors may not be suitable for ambulatory clinical trials at this time.

Original languageEnglish
Pages (from-to)664-671
Number of pages8
JournalMenopause
Volume19
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Symptom Assessment
Menopause
Health
Software
Clinical Trials
Ambulatory Monitoring
Equipment and Supplies
Clothing
Humidity
Demography

Keywords

  • Hot flashes
  • Hygrometer
  • Menopause
  • Sternal skin conductance
  • Symptom assessment
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network. / Carpenter, Janet; Newton, Katherine M.; Sternfeld, Barbara; Joffe, Hadine; Reed, Susan D.; Ensrud, Kristine E.; Milata, Jennifer L.

In: Menopause, Vol. 19, No. 6, 06.2012, p. 664-671.

Research output: Contribution to journalArticle

Carpenter, Janet ; Newton, Katherine M. ; Sternfeld, Barbara ; Joffe, Hadine ; Reed, Susan D. ; Ensrud, Kristine E. ; Milata, Jennifer L. / Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network. In: Menopause. 2012 ; Vol. 19, No. 6. pp. 664-671.
@article{51cbef588e14407a9c4113bf5b1ee0e4,
title = "Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network",
abstract = "Objective: The aim of this study was to evaluate monitors for assessing vasomotor symptoms (VMS) in laboratory and ambulatory settings before use in the Menopause Strategies Finding Lasting Answers for Symptoms and Health network clinical trials testing VMS therapies. Methods: This was a three-phase study. Phase 1 included laboratory testing of the Freedman and prototype Bahr Monitor, phase 2 included laboratory testing of the commercial Bahr Monitor and Biolog, and phase 3 included ambulatory testing of the commercial Bahr Monitor and Biolog. All phases enrolled midlife women with VMS, midlife women without VMS, and young women without VMS. The participants self-reported VMS by pressing event marker buttons. Questionnaires assessed demographics (all phases) and monitor acceptability (phases 2 and 3). Results: Phase I testing was stopped because of sensitivity of the Freedman device to ambient humidity changes and lack of analytic software for the prototype Bahr Monitor. In phases 2 and 3, agreement between event-marked and commercial Bahr Monitor or Biolog-recorded VMS was higher in the laboratory than in the ambulatory setting; however, agreement between monitors was poor in two of three laboratory groups (midlife no VMS and young no VMS) and in all ambulatory groups. During ambulatory monitoring, the mean number of Bahr Monitor VMS was 16.33 in midlife women with VMS, 9.61 in midlife women without VMS, and 14.63 in young women without VMS (software version, March 2011). The Bahr Monitor was more acceptable than the larger Biolog, but feedback reflected annoyance at having to wear a device that itched and was visible under clothing. Conclusions: The Bahr Monitor and Biolog seem suitable for use in controlled laboratory conditions during short periods of time. However, the current versions of these monitors may not be suitable for ambulatory clinical trials at this time.",
keywords = "Hot flashes, Hygrometer, Menopause, Sternal skin conductance, Symptom assessment, Vasomotor symptoms",
author = "Janet Carpenter and Newton, {Katherine M.} and Barbara Sternfeld and Hadine Joffe and Reed, {Susan D.} and Ensrud, {Kristine E.} and Milata, {Jennifer L.}",
year = "2012",
month = "6",
doi = "10.1097/gme.0b013e31823dbbe3",
language = "English",
volume = "19",
pages = "664--671",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network

AU - Carpenter, Janet

AU - Newton, Katherine M.

AU - Sternfeld, Barbara

AU - Joffe, Hadine

AU - Reed, Susan D.

AU - Ensrud, Kristine E.

AU - Milata, Jennifer L.

PY - 2012/6

Y1 - 2012/6

N2 - Objective: The aim of this study was to evaluate monitors for assessing vasomotor symptoms (VMS) in laboratory and ambulatory settings before use in the Menopause Strategies Finding Lasting Answers for Symptoms and Health network clinical trials testing VMS therapies. Methods: This was a three-phase study. Phase 1 included laboratory testing of the Freedman and prototype Bahr Monitor, phase 2 included laboratory testing of the commercial Bahr Monitor and Biolog, and phase 3 included ambulatory testing of the commercial Bahr Monitor and Biolog. All phases enrolled midlife women with VMS, midlife women without VMS, and young women without VMS. The participants self-reported VMS by pressing event marker buttons. Questionnaires assessed demographics (all phases) and monitor acceptability (phases 2 and 3). Results: Phase I testing was stopped because of sensitivity of the Freedman device to ambient humidity changes and lack of analytic software for the prototype Bahr Monitor. In phases 2 and 3, agreement between event-marked and commercial Bahr Monitor or Biolog-recorded VMS was higher in the laboratory than in the ambulatory setting; however, agreement between monitors was poor in two of three laboratory groups (midlife no VMS and young no VMS) and in all ambulatory groups. During ambulatory monitoring, the mean number of Bahr Monitor VMS was 16.33 in midlife women with VMS, 9.61 in midlife women without VMS, and 14.63 in young women without VMS (software version, March 2011). The Bahr Monitor was more acceptable than the larger Biolog, but feedback reflected annoyance at having to wear a device that itched and was visible under clothing. Conclusions: The Bahr Monitor and Biolog seem suitable for use in controlled laboratory conditions during short periods of time. However, the current versions of these monitors may not be suitable for ambulatory clinical trials at this time.

AB - Objective: The aim of this study was to evaluate monitors for assessing vasomotor symptoms (VMS) in laboratory and ambulatory settings before use in the Menopause Strategies Finding Lasting Answers for Symptoms and Health network clinical trials testing VMS therapies. Methods: This was a three-phase study. Phase 1 included laboratory testing of the Freedman and prototype Bahr Monitor, phase 2 included laboratory testing of the commercial Bahr Monitor and Biolog, and phase 3 included ambulatory testing of the commercial Bahr Monitor and Biolog. All phases enrolled midlife women with VMS, midlife women without VMS, and young women without VMS. The participants self-reported VMS by pressing event marker buttons. Questionnaires assessed demographics (all phases) and monitor acceptability (phases 2 and 3). Results: Phase I testing was stopped because of sensitivity of the Freedman device to ambient humidity changes and lack of analytic software for the prototype Bahr Monitor. In phases 2 and 3, agreement between event-marked and commercial Bahr Monitor or Biolog-recorded VMS was higher in the laboratory than in the ambulatory setting; however, agreement between monitors was poor in two of three laboratory groups (midlife no VMS and young no VMS) and in all ambulatory groups. During ambulatory monitoring, the mean number of Bahr Monitor VMS was 16.33 in midlife women with VMS, 9.61 in midlife women without VMS, and 14.63 in young women without VMS (software version, March 2011). The Bahr Monitor was more acceptable than the larger Biolog, but feedback reflected annoyance at having to wear a device that itched and was visible under clothing. Conclusions: The Bahr Monitor and Biolog seem suitable for use in controlled laboratory conditions during short periods of time. However, the current versions of these monitors may not be suitable for ambulatory clinical trials at this time.

KW - Hot flashes

KW - Hygrometer

KW - Menopause

KW - Sternal skin conductance

KW - Symptom assessment

KW - Vasomotor symptoms

UR - http://www.scopus.com/inward/record.url?scp=84862140246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862140246&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31823dbbe3

DO - 10.1097/gme.0b013e31823dbbe3

M3 - Article

VL - 19

SP - 664

EP - 671

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 6

ER -